Connor Clark & Lunn Investment Management Ltd. Has $4.01 Million Position in LifeMD, Inc. (NASDAQ:LFMD)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in LifeMD, Inc. (NASDAQ:LFMD) by 6.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 765,916 shares of the company’s stock after acquiring an additional 48,201 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in LifeMD were worth $4,013,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of LFMD. Russell Investments Group Ltd. grew its stake in LifeMD by 251.0% in the first quarter. Russell Investments Group Ltd. now owns 64,927 shares of the company’s stock valued at $667,000 after purchasing an additional 46,428 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of LifeMD by 12.5% during the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after buying an additional 128,701 shares during the last quarter. Ancora Advisors LLC grew its stake in shares of LifeMD by 97.8% in the 1st quarter. Ancora Advisors LLC now owns 137,760 shares of the company’s stock valued at $1,416,000 after buying an additional 68,110 shares in the last quarter. Virtu Financial LLC acquired a new position in LifeMD in the first quarter worth approximately $249,000. Finally, Calamos Advisors LLC bought a new position in LifeMD during the second quarter valued at approximately $394,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Stock Up 1.9 %

LifeMD stock opened at $5.80 on Friday. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The firm has a fifty day moving average price of $5.03 and a two-hundred day moving average price of $6.14. The firm has a market cap of $251.21 million, a price-to-earnings ratio of -9.06 and a beta of 1.23.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LFMD shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of LifeMD in a research note on Monday, November 11th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. Finally, B. Riley initiated coverage on LifeMD in a research note on Friday, August 23rd. They set a “buy” rating and a $11.00 price target for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $12.00.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.